Disease Indications Articles
Researchers at the University of California, San Francisco, have identified a specific pattern of autoantibodies in the blood that precedes the clinical onset of multiple sclerosis.
The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for Octapharma’s wilate, von Willebrand factor/coagulation factor VIII complex (human) lyophilized powder for solution for intravenous injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).
The Phase IIIb study of emicizumab shows promise for reducing risk of spontaneous and traumatic bleeds in infants with hemophilia A.
A new vaccine may help speed up the process of making antibodies against SARS-CoV-2 by using preexisting immunity to a separate virus (the influenza virus).
A recent study has found that a commercially available plasma p-tau217 (phosphorylated tau 217) immunoassay accurately identified biological Alzheimer’s disease (AD).
In a study, researchers found that fSCIG 10% was more effective in preventing CIDP relapse than placebo, supporting its potential use as maintenance CIDP treatment.
A team of Australian investigators conducted a retrospective cohort study to determine whether there is a significant benefit in more severely affected cases regularly infused with albumin.
The combination of intravenous immune globulin (IVIG) and corticosteroids is a more efficient and rapid treatment for relapsed immune thrombocytopenic purpura (ITP) in adults compared with the use of either therapy alone.
A study has found that early albumin administration in septic shock patients with ARDS was independently associated with a reduction in 28-day mortality.
The U.S. Food and Drug Administration (FDA) has approved nirsevimab to protect newborns from respiratory syncytial virus (RSV).
A study led by scientists at Oregon Health & Science University has found that a type of monoclonal antibody already tested in certain forms of cancer may be a promising treatment in stopping the progression of amyotrophic lateral sclerosis (ALS).
The U.S. Department of Health and Human services has awarded more than $147 million to 49 recipients to advance the Ending the HIV Epidemic in the U.S. initiative, which is part of the ongoing efforts to reduce the number of new infections in the United States by at least 90 percent by 2030.